Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (HRTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · HRTX · as of Sep 30, 2025
Ownership Breakdown
176
Institutional Holders
▲ 1 vs Q2
$192.37M
Total Inst. Value
▼ $79.76M vs Q2
157.94M
Shares Outstanding
freeFloat 83.65%
152.67M
13F Shares Held
▲ 21.20M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
HRTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RUBRIC CAPITAL MANAGEMENT LP pharmaceutical preparations | 29.10M | 18.89% | 18.89% | $36.67B | Nov 14, 2025 | ▲ 2.39M |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 10.24M | 6.65% | 6.65% | $12.90B | Nov 14, 2025 | ▲ 2.39M |
BLACKROCK, INC. pharmaceutical preparations | 9.99M | 6.48% | 6.48% | $12.58B | Nov 12, 2025 | ▼ 114.3K |
CLEARLINE CAPITAL LP pharmaceutical preparations | 9.71M | 6.31% | 6.31% | $12.24B | Nov 14, 2025 | ▲ 8.86M |
VELAN CAPITAL INVESTMENT MANAGEMENT LP pharmaceutical preparations | 8.75M | 5.68% | 5.68% | $11.03B | Nov 14, 2025 | ▲ 1.77M |
VANGUARD GROUP INC pharmaceutical preparations | 8.46M | 5.49% | 5.49% | $10.66B | Nov 7, 2025 | ▼ 11.7K |
PALISADE CAPITAL MANAGEMENT, LP pharmaceutical preparations | 7.33M | 4.76% | 4.76% | $9.23B | Nov 14, 2025 | ▲ 2.24M |
TEJARA CAPITAL LTD pharmaceutical preparations | 4.59M | 2.98% | 2.98% | $5.78B | Nov 4, 2025 | ▲ 72.3K |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 4.25M | 2.76% | 2.76% | $5.36B | Nov 14, 2025 | NEW |
STATE STREET CORP pharmaceutical preparations | 3.65M | 2.37% | 2.37% | $4.60B | Nov 14, 2025 | ▲ 189.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
29
Increased
+27.91M shares4
New Positions
first time holders13
Decreased
−3.45M shares0
Sold Out
fully exitedNet shares change (top 50)
+24.46M
+27.91M / −3.45M
Net new holders
+20
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
HRTX insider trading · insider activity
Source: SEC Form 4
13
Buy transactions
13
Sell transactions
1.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Heron Therapeutics, Inc. (HRTX) is primarily owned by institutional investors, who hold approximately 96.7% of total shares outstanding. Company insiders own approximately 16.35%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Heron Therapeutics, Inc. is RUBRIC CAPITAL MANAGEMENT LP, holding approximately 29.10 million shares — equal to 18.89% of outstanding shares — as of September 30, 2025.
A total of 176 institutional investors currently hold HRTX stock, with a combined institutional value of approximately $192,374,121 as of the most recent 13F filing period.
Frequently asked questions
HRTX ownershipHeron Therapeutics, Inc. (HRTX) is primarily owned by institutional investors, who hold approximately 96.7% of shares. The largest shareholder is RUBRIC CAPITAL MANAGEMENT LP with a 18.89% stake. Company insiders hold 16.35%. Data sourced from SEC Form 13F as of September 30, 2025.